1-20 of 753 Search Results for

gh-growth-hormone

Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Meeting Abstracts
Journal: Diabetes
Diabetes 2019;68(Supplement_1):1559-P
Published: 01 June 2019
... results in lower portal and thus hepatic insulin concentrations in T1D than in T2D or nondiabetic (non-DM) individuals, affecting the GH-IGF axis, as exogenous insulin is subcutaneously delivered in T1D. In this study, we examined how the GH-IGF axis differs by diabetes type, and how it relates to IR...
Journal Articles
Journal: Diabetes
Diabetes 1975;24(9):842–850
Published: 01 September 1975
... in the presence and absence of somatostatin infusion. An oral Previous studies suggested that some of the factors dose of 2.5 mg./kg. 3,5-dimethylpyrazole increased plasma GH from 10.9 to 376.9 ng. per milliliter, which was suppressed by 50 influencing growth hormone (GH)and insulin secre- per cent and 80 per...
Images
Effects of meal intake on circulating concentrations of NEFA, <span class="search-highlight">growth</span> <span class="search-highlight">hormon</span>...
Published: 01 December 2003
FIG. 2. Effects of meal intake on circulating concentrations of NEFA, growth hormone, and glucagon in six normal subjects and in six diabetic subjects during the prandial insulin, basal insulin, and insulin withdrawal studies. GH, growth hormone. ▵, Normal subjects; ▴, diabetic subjects with no in... More
Images
<em>A</em>: Euglycemic pancreatic clamp protocol scheme. <em>B</em>...
Published: 10 May 2016
Figure 1 A: Euglycemic pancreatic clamp protocol scheme. B: Plasma glucose levels for each study group throughout the clamp studies. C: Average insulin infusion rates for each study group throughout the clamp studies. GH, growth hormone. Figure 1. A: Euglycemic pancreatic clamp protocol scheme. B: Plasma glucose levels for each study group throughout the clamp studies. C: Average insulin infusion rates for each study group throughout the clamp studies. GH, growth hormone. More
Images
Plasma glucose levels and insulin infusion rates during euglycemic-hypergly...
Published: 01 July 2002
FIG. 1. Plasma glucose levels and insulin infusion rates during euglycemic-hyperglycemic clamp studies in ND (○) and type 2 diabetic (PC, ▴; GC, ▪) subjects. The light and dark shaded areas represent the euglycemic (t = 180–240 min) and hyperglycemic (t = 300–360 min) study intervals, respectively. GH, growth hormone; SRIF, somatotropin release-inhibiting factor. FIG. 1. Plasma glucose levels and insulin infusion rates during euglycemic-hyperglycemic clamp studies in ND (○) and type 2 diabetic (PC, ▴; GC, ▪) subjects. The light and dark shaded areas represent the euglycemic (t = 180–240 min) and hyperglycemic (t = 300–360 min) study intervals, respectively. GH, growth hormone; SRIF, somatotropin release-inhibiting factor. More
Images
Day 2 <span class="search-highlight">growth</span> <span class="search-highlight">hormone</span> (<span class="search-highlight">GH</span>), cortisol, lactate, NEFA, and glycerol levels (ch...
Published: 21 April 2015
Figure 4 Day 2 growth hormone (GH), cortisol, lactate, NEFA, and glycerol levels (change from baseline to final 15 min of day 2 clamps) in overnight-fasted healthy individuals following either day 1 euglycemia, day 1 euglycemia and alprazolam, day 1 hypoglycemia, or day 1 hypoglycemia and alprazolam. *P < 0.02–0.0009 compared with prior eugly/eugly control (no alprazolam); #P < 0.05–0.006 compared with prior hypo/hypo control (no alprazolam). eugly, euglycemia; hypo, hypoglycemia. Figure 4. Day 2 growth hormone (GH), cortisol, lactate, NEFA, and glycerol levels (change from baseline to final 15 min of day 2 clamps) in overnight-fasted healthy individuals following either day 1 euglycemia, day 1 euglycemia and alprazolam, day 1 hypoglycemia, or day 1 hypoglycemia and alprazolam. *P < 0.02–0.0009 compared with prior eugly/eugly control (no alprazolam); #P < 0.05–0.006 compared with prior hypo/hypo control (no alprazolam). eugly, euglycemia; hypo, hypoglycemia. More
Images
Free fatty acid (FFA) (<em>A</em>), <span class="search-highlight">growth</span> <span class="search-highlight">hormone</span> (<span class="search-highlight">GH</span>) (<em>B</em>...
Published: 01 February 2008
FIG. 3. Free fatty acid (FFA) (A), growth hormone (GH) (B), glucagons (C), and epinephrine (D) concentrations during GLP-1 (•) and placebo (○) infusion. Data are means ± SEM. FIG. 3. Free fatty acid (FFA) (A), growth hormone (GH) (B), glucagons (C), and epinephrine (D) concentrations during GLP-1 (•) and placebo (○) infusion. Data are means ± SEM. More
Images
Plasma epinephrine, ACTH, and <span class="search-highlight">growth</span> <span class="search-highlight">hormone</span> (<span class="search-highlight">GH</span>). Mean (±SE) plasma concen...
Published: 01 September 2004
FIG. 3. Plasma epinephrine, ACTH, and growth hormone (GH). Mean (±SE) plasma concentrations of epinephrine (left), ACTH (middle), and GH (right) during a 30-min baseline phase and 90-min postinjection phase for the three conditions: insulin-eu (red line, n = 9), insulin-hypo (green line, n = 9), and placebo (blue line, n = 9). FIG. 3. Plasma epinephrine, ACTH, and growth hormone (GH). Mean (±SE) plasma concentrations of epinephrine (left), ACTH (middle), and GH (right) during a 30-min baseline phase and 90-min postinjection phase for the three conditions: insulin-eu (red line, n = 9), insulin-hypo (green line, n = 9), and placebo (blue line, n = 9). More
Images
Circulating levels of <span class="search-highlight">growth</span> <span class="search-highlight">hormone</span> (means ± SE). <span class="search-highlight">GH</span> levels tended to be e...
Published: 01 October 2001
FIG. 1. Circulating levels of growth hormone (means ± SE). GH levels tended to be elevated by acipimox during discontinuation of GH replacement, as assessed by AUCGH (B versus D, P = 0.05). GH levels during GH administration were not affected by acipimox (A versus C, P = 0.94). FIG. 1. Circulating levels of growth hormone (means ± SE). GH levels tended to be elevated by acipimox during discontinuation of GH replacement, as assessed by AUCGH (B versus D, P = 0.05). GH levels during GH administration were not affected by acipimox (A versus C, P = 0.94). More
Images
Senolytic or SASP-inhibiting therapies present new opportunities for target...
Published: 17 June 2015
Figure 2 Senolytic or SASP-inhibiting therapies present new opportunities for targeting type 2 diabetes and its complications. Senescent cells that accumulate during aging and obesity may contribute to inflammation, insulin resistance, metabolic dysfunction, and progenitor cell dysfunction through... More
Images
Study protocol. <em>A</em>: Study design. Obese T2DM patients (<ita
Published: 13 November 2014
Figure 1 Study protocol. A: Study design. Obese T2DM patients (n = 16) and obese normoglycemic (n = 16) and lean (n = 16) subjects were studied in a randomized, placebo-controlled, crossover study. The acute effects of either intravenous exenatide or exenatide together with the GLP-1 receptor antagonist exendin 9-39 on CNS appetite and reward responses to visual food-related stimuli were measured, using fMRI, during a somatostatin pituitary-pancreatic clamp (glucose 5 mmol/L) after an overnight fast. After the fMRI, subjects were presented a lunch buffet to assess energy intake. Hunger and nausea scores were taken at t = 0, 50, 110, 150, and 180 min. B: fMRI paradigm. One of the three runs within one fMRI session. Each run consisted of six blocks of pictures, two each of high-calorie foods, low-calorie foods, and neutral pictures. The blocks were separated by 9 s of gray blank screen with a fixation cross. The order of blocks was randomized with the constraint that a given picture category was not followed by the same category. Cal, calorie; GH, growth hormone. Figure 1. Study protocol. A: Study design. Obese T2DM patients (n = 16) and obese normoglycemic (n = 16) and lean (n = 16) subjects were studied in a randomized, placebo-controlled, crossover study. The acute effects of either intravenous exenatide or exenatide together with the GLP-1 receptor antagonist exendin 9-39 on CNS appetite and reward responses to visual food-related stimuli were measured, using fMRI, during a somatostatin pituitary-pancreatic clamp (glucose 5 mmol/L) after an overnight fast. After the fMRI, subjects were presented a lunch buffet to assess energy intake. Hunger and nausea scores were taken at t = 0, 50, 110, 150, and 180 min. B: fMRI paradigm. One of the three runs within one fMRI session. Each run consisted of six blocks of pictures, two each of high-calorie foods, low-calorie foods, and neutral pictures. The blocks were separated by 9 s of gray blank screen with a fixation cross. The order of blocks was randomized with the constraint that a given picture category was not followed by the same category. Cal, calorie; GH, growth hormone. More
Journal Articles
Journal: Diabetes
Diabetes 2001;50(11):2438–2443
Published: 01 November 2001
...Jun Kamegai; Hideki Tamura; Takako Shimizu; Shinya Ishii; Hitoshi Sugihara; Ichiji Wakabayashi Ghrelin, an endogenous ligand for the growth hormone secretagogue receptor (GHS-R), was originally purified from the rat stomach. Like the synthetic growth hormone secretagogues (GHSs), ghrelin...
Images
Experimental design. For additional details see the text. <span class="search-highlight">GH</span>, human <span class="search-highlight">growth</span> ...
Published: 01 February 2002
FIG. 1. Experimental design. For additional details see the text. GH, human growth hormone; ICG, indocyanine green. FIG. 1. Experimental design. For additional details see the text. GH, human growth hormone; ICG, indocyanine green. More
Journal Articles
Journal: Diabetes
Diabetes 1972;21(3):175–177
Published: 01 March 1972
...Richard L Lipman, M.D.; Andrew L Taylor, M.D.; Patricia Conly, M.D.; Daniel H Mintz, M.D. The metabolic clearance rate (MCR) of radio-labeled growth hormone (GH) was measured in eleven recently diagnosed patients with juvenile-onset diabetes mellitus and in seven healthy nonhospitalized healthy...
Images
Cellular distribution pattern of glucokinase mRNA in mouse pituitary as rel...
Published: 01 July 2006
FIG. 3. Cellular distribution pattern of glucokinase mRNA in mouse pituitary as related to expression of ACTH/POMC and growth hormone (GH). RNA in situ hybridization studies are shown for glucokinase (AC), ACTH/POMC (DF), or GH (GI). Images in A, D, and G were taken at 4×, in B, E, and H at 20×, and in C, F, and I at 40× magnification. Boxes indicate areas shown at higher magnification. FIG. 3. Cellular distribution pattern of glucokinase mRNA in mouse pituitary as related to expression of ACTH/POMC and growth hormone (GH). RNA in situ hybridization studies are shown for glucokinase (A–C), ACTH/POMC (D–F), or GH (G–I). Images in A, D, and G were taken at 4×, in B, E, and H at 20×, and in C, F, and I at 40× magnification. Boxes indicate areas shown at higher magnification. More
Images
Arterialized plasma concentrations of glucagon (<em>A</em>), epinep...
Published: 02 December 2021
Figure 3 Arterialized plasma concentrations of glucagon (A), epinephrine (B), norepinephrine (C), growth hormone (D), and cortisol (E) during hyperinsulinemic-hypoglycemic clamp studies after 4 weeks of placebo (red squares) or dapagliflozin (Dapa; blue circles) in the crossover study. Data are summarized as medians and 95% CIs. Within-participant differences (placebo minus dapagliflozin) for counterregulatory hormones AUC in response to hypoglycemia for glucagon (F), epinephrine (G), norepinephrine (H), growth hormone (GH; I), and cortisol (J). Black vertical lines signify the median differences for the entire study cohort. More
Journal Articles
Journal: Diabetes
Diabetes 1994;43(1):68–72
Published: 01 January 1994
...Mitchell E Geffner; Noelle Bersch; Robert C Bailey; David W Golde Growth hormone (GH) and insulin have both mitogenic and metabolic actions. The growth-promoting effects of GH in vivo are thought to be mediated by insulin-like growth factor-I (IGF-I), whereas the metabolic effects of GH are thought...
Journal Articles
Journal: Diabetes
Diabetes 2001;50(4):707–709
Published: 01 April 2001
...Matthias Tschöp; Christian Weyer; P. Antonio Tataranni; Viswanath Devanarayan; Eric Ravussin; Mark L. Heiman Ghrelin is a novel endogenous natural ligand for the growth hormone (GH) secretagogue receptor that has recently been isolated from the rat stomach. Ghrelin administration stimulates GH...
Images
Day 2 epinephrine, norepinephrine, glucagon, pancreatic polypeptide (PP), g...
Published: 23 May 2016
Figure 1 Day 2 epinephrine, norepinephrine, glucagon, pancreatic polypeptide (PP), growth hormone (GH), and cortisol responses (change from baseline to final 15 min of day 2 clamps) in overnight-fasted healthy individuals after either day 1 euglycemia, day 1 euglycemia and alprazolam, or day 1 hypoglycemia. *P < 0.01–0.002 significantly reduced compared with prior euglycemia/euglycemia control. Figure 1. Day 2 epinephrine, norepinephrine, glucagon, pancreatic polypeptide (PP), growth hormone (GH), and cortisol responses (change from baseline to final 15 min of day 2 clamps) in overnight-fasted healthy individuals after either day 1 euglycemia, day 1 euglycemia and alprazolam, or day 1 hypoglycemia. *P < 0.01–0.002 significantly reduced compared with prior euglycemia/euglycemia control. More
Journal Articles
Journal: Diabetes
Diabetes 1990;39(10):1251–1256
Published: 01 October 1990
...Cheryl A Conover; Peter C Butler; Michael Wang; Robert A Rizza; Phillip D K Lee Insulinlike growth factor binding protein 1 (IGFBP-1) has been shown to modulate the metabolic and mitogenic actions of the growth hormone (GH)- dependent peptide insulinlike growth factor I. Previous studies showed...